文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

艾曲泊帕治疗无原始细胞增多伴血小板减少的MDS或CMML:法国多中心回顾性真实世界研究

Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
PubMed 文献 · Br J Haematol · 2021-06-20

这项法国多中心回顾性真实世界研究纳入50例MDS和11例CMML患者,均无骨髓原始细胞增多且血小板<50×10^9/L,评估艾曲泊帕的疗效与安全性。结果显示47例(77%)获血小板应答,中位应答持续8个月,仅6例(10%)发生血栓事件,4例(7%)进展为急性髓系白血病。

要点

  • 艾曲泊帕在无原始细胞增多的MDS/CMML伴血小板减少患者中血小板应答率达77%。
  • 中位应答持续8个月,停药后仍应答者中位随访16个月未见复发。
  • 血栓事件发生率10%,多见于有动脉或静脉血栓史者。

核心结论

  • 艾曲泊帕在无原始细胞增多的MDS/CMML伴血小板减少患者中有效且总体耐受良好。

研究设计与样本

  • 法国多中心回顾性真实世界研究,纳入50例MDS和11例CMML患者,均无骨髓原始细胞增多且血小板<50×10^9/L。

主要发现

  • 47例(77%)患者出现血小板应答,中位应答持续8个月(范围0-69个月)。
  • 8例停药时仍应答者中位随访16个月(范围6-23个月)均未复发。
  • 36%患者接受抗凝或抗血小板治疗,仅10%发生≥3级出血事件。
  • 6例(10%)发生血栓事件,其中5例有动脉或静脉血栓病史。
  • 4例(7%)进展为急性髓系白血病。

临床怎么用

  • 对无原始细胞增多的MDS/CMML伴血小板减少患者,艾曲泊帕可作为治疗选择。
  • 治疗前应评估血栓病史,有动脉或静脉血栓史者需谨慎使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite a moderate prevalence in low-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML), thrombocytopenia remains a risk of severe bleeding and therapeutic options are still limited. There are only a few studies with eltrombopag (ELT), a thrombopoietin receptor agonist, in those patients. In this retrospective multicentre study, ELT was used in 50 patients with MDS and 11 with CMML, with no excess of marrow blasts and platelet counts of <50 × 109 /l in a 'real-life' situation. Platelet response occurred in 47 (77%) patients. The median (range) duration of response was 8 (0-69) months. None of the eight still responders who discontinued ELT had relapsed, at a median (range) of 16 (6-23) months after ELT discontinuation. Although 36% of the patients were anti-coagulated or anti-aggregated only 10% of patients had Grade ≥3 bleeding events. Thrombotic events were observed in six (10%) patients, who all but one had a medical history of arterial or venous thrombosis. Progression to acute myeloid leukaemia occurred in four (7%) patients. In this first 'real-life' study, ELT was effective and generally well tolerated in patients with MDS/CMML without excess blasts.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Comont T, Meunier M, Cherait A, et al. Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study. Br J Haematol. 2021. PMID: 34151423. doi:10.1111/bjh.17539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。